CEL-SCI Corporation (CVM)
-NYSE MKT 0.25 
0.00(0.40%) May 24, 4:00PM EDT
| Prev Close: | 0.25 |
|---|
| Open: | 0.25 |
|---|
| Bid: | 0.25 x 600 |
|---|
| Ask: | 0.28 x 7000 |
|---|
| 1y Target Est: | 0.80 |
|---|
| Beta: | 1.83 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.25 - 0.25 |
|---|
| 52wk Range: | 0.21 - 0.47 |
|---|
| Volume: | 488,933 |
|---|
| Avg Vol (3m): | 1,074,060 |
|---|
| Market Cap: | 77.31M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.04 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- CEL-SCI Corporation To Present At The Second Annual Marcum LLP MicroCap ConferencePR Newswire(Thu, May 23)
- CEL SCI CORP FinancialsEDGAR Online Financials(Fri, May 17)
- CEL-SCI Corporation Reports Second Quarter 2013 Financial ResultsBusiness Wire(Fri, May 10)
- CEL SCI CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- CEL-SCI presents data on LEAPS vaccineat theflyonthewall.com(Mon, May 6)
- CEL-SCI Presents Data Showing LEAPS Vaccine is Successful in Reducing Rheumatoid Arthritis Index Score in a Second Animal ModelBusiness Wire(Mon, May 6)
- CEL-SCI To Present at the American Association of Immunologists 100th Annual Meeting on Saturday May 4thBusiness Wire(Fri, May 3)
- Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail!at TheStreet(Fri, Apr 26)
- Bullish $10 Million Bet Placed by CRO After CEL-SCI Acts to Accelerate Phase III EnrollmentMarketwired(Wed, Apr 24)
- CEL-SCI provides update on phase III clinical trial of Multikineat theflyonthewall.com(Tue, Apr 23)
- CEL-SCI Corporation Provides Update on Phase III Clinical TrialBusiness Wire(Tue, Apr 23)
- Three Biotech Stocks With Low Price But Great Potentialat Seeking Alpha(Tue, Apr 16)
- BioCryst Won't Profit From Bird Flu Outbreak in Chinaat TheStreet(Mon, Apr 8)
- CEL-SCI Corporation Announces That NIAID Collaborators Have Submitted Bird Flu Study for Publication to Prestigious Scientific JournalBusiness Wire(Mon, Apr 8)
- CEL-SCI's Price Rebound Looks StrongMarketwired(Thu, Apr 4)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 447.50 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Sep-13)
: | -0.05 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.02 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
CEL-SCI Corporation engages in the research and development of drugs and vaccines. The companys principal product, Multikine, is under Phase III clinical trial for the treatment of head and neck cancer.
View More